Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CBX7 | O95931 | 1/20 | 0.37 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565234 | 0.85 | KMT2A (0.41) | KMOTP53LMNAKDM4EIDO1 | |
| SCHEMBL29670894 | 0.85 | KMO (0.42) | KMOIDO1 | |
| SCHEMBL18329427 | 0.85 | KMO (0.42) | KMOIDO1 | |
| SCHEMBL16186525 | 0.83 | KMO (0.43) | KMOIDO1 | |
| SCHEMBL16176506 | 0.83 | KMO (0.38) | KMOIDO1 | |
| SCHEMBL16186530 | 0.82 | ALDH1A1 (0.39) | TP53LMNACBX7CDYL2CDYL | |
| SCHEMBL16176695 | 0.81 | KMO (0.44) | KMOIDO1 | |
| SCHEMBL5293998 | 0.79 | KMT2A (0.47) | TP53LMNAKDM4EKMT2A | |
| SCHEMBL18329422 | 0.77 | IDO1 (0.44) | IDO1 | |
| SCHEMBL29670897 | 0.77 | IDO1 (0.44) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8937087-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD1, DRD2, OPRD1 | KMO 1970/4885TP53 1338/4885LMNA 4806/4885 |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD2, DRD1, OPRD1 | KMO 2179/4885TP53 1325/4885LMNA 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.